Is Aclaris Therapeutics Inc (ACRS) undervalued? · rev $18.7M
Aclaris Therapeutics Inc (ACRS) is a biotechnology company listed on NASDAQ.
This page asks whether Aclaris Therapeutics Inc (ACRS) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ACRS revenue for 2024-12-31 was $18.7M. Net income was -$132.1M. Revenue was down 40.1% from 2023-12-31 to 2024-12-31. ACRS currently screens at market cap $615.9M.
ACRS currently screens at market cap $615.9M. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ACRS 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ACRS to the stock page model before you treat a low multiple as a gift.
Not investment advice.